Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer

Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer

Saved in:

Bibliographic Details
Main Authors:	Yang Tan, Kai Liu, Chengpei Zhu, Shanshan Wang, Yunchao Wang, Jingnan Xue, Cong Ning, Nan Zhang, Jiashuo Chao, Longhao Zhang, Junyu Long, Xiaobo Yang, Daobing Zeng, Lijin Zhao, Haitao Zhao
Format:	Article
Language:	English
Published:	Springer 2025-04-01
Series:	Cancer Immunology, Immunotherapy
Online Access:	https://doi.org/10.1007/s00262-025-03999-0
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment
by: Shiyun Cui, et al.
Published: (2025-04-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
by: Yun Liu, et al.
Published: (2023-02-01)

Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Qingyu Xu, et al.
Published: (2025-05-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
by: Longhao Zhang, et al.
Published: (2024-06-01)

Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study
by: Jiajin Yang, et al.
Published: (2025-04-01)

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01)

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01)

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
by: Liu DY, et al.
Published: (2024-11-01)

Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer
by: Shao-Jing Wang, et al.
Published: (2025-03-01)

Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study
by: Qi-Yu Chi, et al.
Published: (2025-07-01)

Local–regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study
by: Shuofeng Li, et al.
Published: (2025-07-01)

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
by: Haihong Zhu, et al.
Published: (2024-07-01)

Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
by: Shimpei Yamashita, et al.
Published: (2025-05-01)

Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2025-01-01)

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
by: Weihao Zhang, et al.
Published: (2025-06-01)

Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies
by: Jingnan Xue, et al.
Published: (2025-08-01)

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
by: Jitong Zhou, et al.
Published: (2025-07-01)

Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma
by: Junying Wang, et al.
Published: (2025-06-01)

Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
by: JIANG Jiayun, et al.
Published: (2024-11-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma
by: Ming Zhao, et al.
Published: (2021-06-01)

Efficacy Analysis of TACE Combined with Lenvatinib and PD-1 Inhibitors in the Treatment of Hepatitis B Virus-Related Unresectable Hepatocellular Carcinoma
by: Yu J, et al.
Published: (2025-07-01)

Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma: a single-arm Meta analysis
by: Guo-Xin HUANG, et al.
Published: (2023-12-01)

Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
by: Ilya Tsimafeyeu, et al.
Published: (2025-04-01)

Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab
by: A. Pawsey, et al.
Published: (2025-05-01)

Survival Benefit of Adjuvant Treatment with Huaier Granules Plus Lenvatinib in Hepatocellular Carcinoma Patients with Tumors Greater Than 5 cm After Radical Hepatectomy
by: Liu C, et al.
Published: (2025-07-01)

Efficacy and safety of local–regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study
by: Shuofeng Li, et al.
Published: (2025-05-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Gallbladder metastasis in invasive ductal breast cancer with concurrent gallstones and gallbladder carcinoma
by: Rujuan Wang, et al.
Published: (2025-07-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

PTEN as a prognostic factor for radiotherapy plus immunotherapy response in nasopharyngeal carcinoma
by: Jiaxing Guo, et al.
Published: (2025-04-01)

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib
by: Huaxiang Wang, et al.
Published: (2025-01-01)

Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report
by: Shinkuro Yamamoto, et al.
Published: (2025-09-01)

Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
by: Jin M, et al.
Published: (2024-11-01)

Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study
by: Miao Xue, et al.
Published: (2025-06-01)